Tokyo, Oct. 5 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063160) titled 'Physician and Patient Preferences Study in IgA Nephropathy: A Discrete Choice Experiment' on Oct. 5.
Study Type:
Observational
Primary Sponsor:
Institute - Otsuka Pharmaceutical Co., Ltd.
Condition:
Condition - IgA nephropathy
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To quantify the preferences of patients with IgA nephropathy and physicians involved in IgA nephropathy care in Japan for multiple treatment attributes and to determine the relative importance of these attributes.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - Patients
1. Diagnosis of IgAN confirmed by renal biopsy.
2. An eGFR of >=20 mL/min/1.73 m2 at the most recent renal function assessment.
3. Under medical care or follow-up at the time of the survey and considered eligible for participation by the treating physician.
4. Able to complete the survey independently.
Physicians
1. Board-certified nephrologists.
2. Experience providing pharmacological treatment to patients with IgAN within the past 12 months.
3. Agreement to participate in the survey.
Key exclusion criteria - Patients
1.Patients with secondary IgA nephropathy (IgAN).
2.Patients who are currently receiving dialysis therapy.
3.Patients with a history of kidney transplantation.
Physicians
1.No specific exclusion criteria.
Target Size - 400
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 09 Month 07 Day
Date of IRB - 2026 Year 09 Month 07 Day
Anticipated trial start date - 2026 Year 11 Month 01 Day
Last follow-up date - 2027 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072291
Disclaimer: Curated by HT Syndication.
